| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,620 | 2,810 | 19.02. | |
| 2,620 | 2,810 | 19.02. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 315,00 | 56.000 | |||
| 150,00 | 10 | |||
| 2,810 | 3.200 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/b8fk.htm [/URL] | ||||
| 3.354 | 2,630 | |||
| 996 | 2,350 | |||
| 1.099 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 5.449 | 10,866 | 59.210 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:20:34 | 2,770 | 32 |
| 15:12:42 | 2,760 | 36 |
| 11:28:51 | 2,620 | 32 |
| 09:04:37 | 2,630 | 13 |
| Tagesumsatz Xetra | -0,080 -2,89 % | 1.161 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BIOFRONTERA AG zeigt jetzt strukturelle Stärke | 10 | Maximilian Berger | ||
| BIOFRONTERA Aktie jetzt für 0€ handeln | |||||
| Di | Biofrontera completes key study for Ameluz skin treatment expansion | 21 | Investing.com | ||
| Sa | PTA-Adhoc: Biofrontera AG: Erhöhung Prognose | 3.170 | Dow Jones News | DJ PTA-Adhoc: Biofrontera AG: Erhöhung Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges
Biofrontera AG: Erhöhung Prognose
Leverkusen... ► Artikel lesen | |
| 11.02. | Biofrontera's Ameluz SNDA For Superficial Basal Cell Carcinoma Accepted By FDA | 30 | RTTNews | ||
| 09.02. | Biofrontera's Ameluz shows strong results in actinic keratosis trial | 41 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Do | Regeneron Pharmaceuticals, Inc.: Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) | GlobeNewswire (Europe) | FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved... ► Artikel lesen | |
| Do | NovaBridge Biosciences: NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform | GlobeNewswire (Europe) | Appointment is a positive endorsement of NovaBridge's unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around... ► Artikel lesen | |
| Do | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | GlobeNewswire (Europe) | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| Do | Kane Biotech Inc.: Kane Biotech Expands Commercial Activities in the United States | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has signed non-exclusive distribution/sales agreements... ► Artikel lesen | |
| Do | XFRA CORRECTION - DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.02.2026 | Xetra Newsboard | The following instrument will not be delisted from Boerse Frankfurt:Das folgenden Instrument bleibt weiterhin handelbar auf Boerse Frankfurt:ISIN NameCH0308403085 GENEURO SA SF-,05 ► Artikel lesen |